QYResearch: The Global market size for Antibody Drug Conjugate reached 2.21 Billion USD in 2016

Analyst：Carol （Jia Li）

Company: QYResearch

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

According to the study conducted by QYResearch, The large downstream demand for Antibody Drug Conjugate has been and still remains fairly stable. The Global market size for Antibody Drug Conjugate reached 2.21 Billion USD in 2016 from 121 Million USD in 2012.

North America ranks the top in terms of global market size of Antibody Drug Conjugate, it consists of 59.12% of the international market in 2016. Europe comes the second, with 27.70% of the global market. Asia Pacific consists of 6.54%of the Antibody Drug Conjugate market in the same year.

Takeda ranks the first in terms of revenue share in Global market of Antibody Drug Conjugate, occupies 54.17% of market share in 2016; While, Roche, with a market share of 35.11%, comes the second; The other companies consist of approximately 10.72% of the global market in 2016.

Despite the presence of fierce competition and the trend of price decrease, due to the stable demand, together with the development of the related industries. Investors are quite optimistic about this industry. There will be more new investors entering this field in the near future.   

In the next five years, the global consumption of Antibody Drug Conjugate will show upward tendency further, market size is expected to be about 3 Billion USD by 2022.  

More Info: http://www.qyresearchglobal.com/goods-1018789.html

This article was first released by QYResearch analyst, if reproduced, please indicate the source.

Media Contact: press@qyresearch.com

Analyst: lijia@qyresearch.com

Marketing: sales@qyresearch.com